PSS14 COST-UTILITY ANALYSIS OF RANIBIZUMAB (LUCENTIS®) IN WET-AMD BASED ON REAL-LIFE DATA COLLECTED IN THE HELIOS STUDY AFTER RANIBIZUMAB REIMBURSEMENT IN BELGIUM
May 1, 2011, 00:00
10.1016/j.jval.2011.02.316
https://www.valueinhealthjournal.com/article/S1098-3015(11)00455-4/fulltext
Title :
PSS14 COST-UTILITY ANALYSIS OF RANIBIZUMAB (LUCENTIS®) IN WET-AMD BASED ON REAL-LIFE DATA COLLECTED IN THE HELIOS STUDY AFTER RANIBIZUMAB REIMBURSEMENT IN BELGIUM
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)00455-4&doi=10.1016/j.jval.2011.02.316
First page :
A55
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
868